Drugs / TACH101
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05076552 | Feb 2023 → Jul 2025 | metastatic neoplasm | Tachyon Therapeutics, Inc. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TACH101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05076552 ↗ |
| Route | Oral | “Orally via capsules” NCT05076552 ↗ |